[Therapeutic hyperosmolarity].
D000328:Adult; D001639:Bicarbonates / Q000627:therapeutic use; D001803:Blood Transfusion; D001927:Brain Diseases / Q000139:chemically induced*; D056486:Chemical and Drug Induced Liver Injury; D003975:Diazepam / Q000506:poisoning; D005260:Female; D005947:Glucose / Q000009:adverse effects* / Q000627:therapeutic use; D006323:Heart Arrest / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D006982:Hypertonic Solutions / Q000009:adverse effects*; D007263:Infusions, Parenteral; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008680:Metaraminol / Q000627:therapeutic use; D009336:Necrosis / Q000139:chemically induced; D009994:Osmolar Concentration; D010182:Pancreatic Diseases / Q000139:chemically induced; D010634:Phenobarbital / Q000506:poisoning; D011041:Poisoning / Q000188:drug therapy*; D014325:Tromethamine / Q000009:adverse effects
D001639:Bicarbonates; D006982:Hypertonic Solutions; D007328:Insulin; D014325:Tromethamine; D008680:Metaraminol; D005947:Glucose; D003975:Diazepam; D006854:Hydrocortisone; D010634:Phenobarbital
L'hyperosmolarité thérapeutique.